(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠
| 中文名称 | (2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠 |
|---|---|
| 中文同义词 | 溴酚酸钠;溴芬那酸钠水合物;溴芬酸钠水合物;溴芬酸钠;溴芬那酸钠;(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠;(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠水合物;溴芬酸钠120638-55-3 |
| 英文名称 | Bromfenac Sodium |
| 英文同义词 | bromfenac sodium salt sesquihydrate;Benzeneacetic acid,2-amino-3-(4-bromobenzoyl)-,sodium salt,hydrate(2:2:3);Bromfenac sodiu;Sodium (2-amino-3-(4-bromobenzoyl)phenyl)acetate;Benzeneacetic acid, 2-amino-3-(4-bromobenzoyl)-, monosodium salt, hydrate (2:3);Bromfenac ophthalmic;Bromfenac ophthalmic solution;Duract |
| CAS号 | 120638-55-3 |
| 分子式 | C15H11BrNNaO3 |
| 分子量 | 356.15 |
| EINECS号 | 695-342-6 |
| 相关类别 | 小分子抑制剂;有机原料;小分子抑制剂，天然产物;眼科用药;医药 眼科用药;Intermediates & Fine Chemicals;Pharmaceuticals;Inhibitors;医药原料;原料药;生物活性分子-API;API |
| Mol文件 | 120638-55-3.mol |
| 结构式 |  |
(2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠 性质
| 熔点 | 268-270°C (dec.) |
|---|---|
| 储存条件 | Refrigerator |
| 溶解度 | DMSO：≥100mg/mL（260.98mM）；水：≥100mg/mL（260.98mM） |
|
COX-1 5.56 nM (IC 50 ) |
COX-2 7.45 nM (IC 50 ) |
Bromfenac (90 μg/mL; 48 h) inhibits TGF-b1-induced extracellular matrix (ECM) synthesis and myofibroblast activation in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) decreases the protein and mRNA expression levels of FN, COL3, a-SMA, and survivin in a dose-dependent manner in HConFs and HPFs.
Bromfenac (30-90 μg/mL; 48 h) declines the phosphorylated protein levels of AKT, ERK1/2, and GSK-3b-S9 with dosage in HPFs and HConFs.
Bromfenac (0.0032-3.16%; 100 or 200 μL; rubbed onto the backs) produces significant anti-inflammatory activity at concentrations as low as 0.1% (4 h pretreatment time) or 0.32% (18h pretreatment time) in rats.
Bromfenac (0.032-3.16%; 100 μL; rubbed onto the paws) produces dose-related anti-inflammatory activity in rats.
Bromfenac (0.032-1.0%; 50 μL) is 26 times more potent than indomethacin in blocking the erythema when applied directly onto the skin area exposed to UV light in guinea pigs.
Bromfenac (0.0032-0.1%; 50μL; rubbed onto the uninjected paw for 4 h per day and 5 days per week) produces a dose and time dependent reduction in the paw volume of both hind limbs in rats.
Bromfenac (0.32%; 50μL; rubbed onto the abdomen) produces significant blockade of abdominal constriction to ACh challenge in mice.
| Animal Model: | Male Sprague-Dawley rats (150-250 g) are injected carrageenan |
| Dosage: | 0.0032, 0.01, 0.032, 0.1, 0.32, 1.0, 3.16% (100 or 200 μL) |
| Administration: | Rubbed onto the backs before 1-72 h of injected carrageenan |
| Result: |
Produced significant anti-inflammatory activity when applied 1, 2, and 4 h prior to carrageenan challenge at 0.32%.
Applied 1 or 4 h prior to carrageenan challenge was active, but not when applied 24 h (or longer) prior to challenge at 0.2%. |
安全信息
| 更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
|---|---|---|---|---|---|
| 2024/01/25 | HY-B1888B | Bromfenac sodium hydrate | 5 mg | 225元 | |
| 2024/01/25 | HY-B1888B | (2-氨基-3-(4-溴苯甲酰)苯基)乙酸钠 Bromfenac sodium hydrate | 120638-55-3 | 10mM * 1mLin DMSO | 248元 |